Connect Biopharma Holdings (CNTB) Return on Sales (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Return on Sales for 3 consecutive years, with 1.15% the latest figure, recorded in Q1 2026.

• Quarterly Return on Sales changed N/A year-over-year to 1.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.77% (changed N/A YoY) and the FY2025 annual result came in at 8.67%, down 866.0% from the prior year.
• Return on Sales rose to 1.15% in Q1 2026 per CNTB's latest filing, from 8.67% in the prior quarter.
• Over the last five years, Return on Sales for CNTB reached as high as 0.11% in Q3 2024 and fell as low as 10.75% in Q3 2025.
• A 3-year average of 3.91% and a median of 1.92% in 2026 frame the typical range for Return on Sales.
• The largest YoY upside for Return on Sales was 854 bps in 2025 against a maximum downside of 1064 bps in 2025.
• Year by year, Return on Sales stood at 0.13% in 2024, then tumbled by 6694 bps to 8.67% in 2025, then soared by 87 bps to 1.15% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 1.15%, 8.67%, and 10.75% for Q1 2026, Q4 2025, and Q3 2025 respectively.